Figure 3 - uploaded by Young Jeung Park
Content may be subject to copyright.
Left column (A, B: Limbal-conjunctival autograft without 0.02% MMC, C, D: Limbal-conjunctival autograft with 0.02% MMC) Images of preoperative fleshy grade 3 nasal primary pterygium. Right column (E, F: Limbal- conjunctival autograft without 0.02% MMC, G, H: Limbal-conjunctival autograft with 0.02% MMC) Images of the LCAT of the same patients 6 months after the surgery. Well-positioned graft and reestablishment of the normal limbal architecture are observed with no signs of recurrences in all subjects. Notice: The lack of scar on the donor and recipient conjunctiva due to the use of bioadhesives, and the cosmetic advantage due to appropriate size of conjuctival flap after extensive pterygium excision are apparent.
Source publication
To evaluate the effectiveness of Mitomycin C used as a combined therapy along with limbal-conjunctival autograft for primary pterygium.
Similar publications
Purpose:
To identify the exact time point during after following pterygium excision with a modified technique of sutureless, glueless limbal-conjunctival autograft, when stabilization of the change in corneal curvature is achieved; correlate size of pterygium with uncorrected visual acuity and astigmatism at baseline, and assess changes in these p...
Purpose:
To compare horizontal and vertical split conjunctival autograft technique in the management of double head pterygium.
Methods:
Retrospective analysis of 96 and 99 eyes with double head pterygia that underwent horizontal (Group 1) and vertical (Group 2) split conjunctival autografting, respectively. Comparison of recurrence rates and oth...
Pterygium is a multifactorial proliferative pathologic change of bulbar conjunctiva. The purpose of this study was to determine the effect of the duration of exposure to solar radiation (expressed in years) on the incidence of positive cyclooxygenase-2 (COX-2) finding in conjunctival tissue in two groups of patients. Group 1 consisted of 68 patient...
A 50-year-old man with recurrent pterygium and a 46-year-old woman with primary pterygium underwent surgery using a novel autograft transfer technique that facilitates autograft suturing and ensures correct graft orientation. After removing the pterygium, three edges of the autograft were cut. The autograft was flipped first over the uncut edge and...
Introduction: Various pro-inflammatory cytokines and growth factors have been implicated in the pathogenesis of pterygium (Pt); however, the effect of cytokines produced by helper T lymphocytes (Th) has been poorly studied. To date, only interleukin 4 (IL-4) from Th lymphocytes has been linked to Pt recurrence. Therefore, this study aimed to evalua...
Citations
Purpose: We evaluated a combination of intraoperative mitomycin C (MMC) and amniotic membrane transplantation (AMT) for treating recurrent pterygia. Methods: We retrospectively analyzed 40 eyes of 39 patients with recurrent pterygia who underwent AMT from December 2007 to July 2015 and who were followed-up for a minimum of 12 months. In all, 22 eyes received intraoperative MMC (group A) and 18 did not (group B). Recurrence rates and complications were compared between the two groups. Results: Conjunctival recurrence was noted in two and corneal recurrence was noted in four eyes of group A (27.3%); the figures for group B were four and three (38.9%). These recurrence rates were not significantly different (p = 0.545). In five cases with preoperative symblepharon, this condition recurred when MMC was not used (two eyes) but not when MMC was used (three eyes). No major complications such as necrotizing scleritis, scleromalacia, or corneal ulcer were observed in either group after surgery. Conclusions: Intraoperative adjunct MMC therapy did not significantly inhibit recurrence after AMT for treating recurrent pterygia but may reduce the recurrence rate of symblepharon. 2018 The Korean Ophthalmological Society.
To compare postoperative recurrence rates of pterygium surgery with amniotic membrane transplantation with and without mitomycin C.
